For the past 30 years, a diagnosis of acute myeloid leukemia (AML) has been a death sentence for many patients. Unlike most other forms of cancer, treatment advances have been few and far between, and an archaic chemo cocktail remains the decades-long standard of care. This has lead to the worst 5-year survival rate of any form of adult leukemia, and the hope for long-term survival little more than wishful thinking.
Now with Rydapt, the future has become brighter. As the first targeted agent approved in decades, patients will finally experience the benefit of sustained survival benefits. The Unicorn, embedded in everyday scenarios like the subway, represents how the myth of extended survival is finally a reality in AML.
Print advertisement created by Harrison and Star, United States for Novartis, within the category: Pharmaceutical.
Creative Directors: Mark Friedman, Mike Norkin, Dean Szostczuk, Josh Eastman
Art Directors: Dean Szostczuk, Matt Lee, Donna Tedesco, Matt Kemler
Copywriters: Josh Eastman, Garrett Allen, Brian McCoy
Photographer: Vincent Dixon
Digital Artists: Clive Biley, David Brungard, James Cullinane
Why Apple Is Obsessed With the Music of NYC Duo Sofi TukkerRead More
How Hyundai Fell in Love With a Haunting Cover of Steve Winwood's 'Higher Love'Read More
Maren Morris and Zedd Take No. 1 (Again) While New TV Shows ReignRead More
Q&A: AMV’s Rosie Arnold on Branded Content, and Tips for Entering WorkRead More